A Blood-based Gene-expression Scoring System for Cancer Screening in Patients With Branch-duct Intraductal Papillary Mucinous Neoplasms

Background: In patients with branch-duct intraductal papillary mucinous neoplasms (BD-IPMN), we aimed to develop a novel blood-based biomarker utilizing a gene-expression profile for the detection of pancreatic malignancies, such as IPMN-derived carcinoma (IPMC) or pancreatic ductal adenocarcinoma (...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-11, Vol.40 (11), p.6551-6561
Main Authors: Suzuki, Rei, Tamura, Hirosumi, Honma, Reiko, Konno, Naoki, Irie, Hiroki, Takagi, Tadayuki, Sugimoto, Mitsuru, Asama, Hiroyuki, Sato, Yuki, Yoshinori, Okubo, Nakamura, Jun, Takasumi, Mika, Kato, Tsunetaka, Hashimoto, Minami, Hikichi, Takuto, Imai, Jun-Ichi, Watanabe, Shinya, Ohira, Hiromasa
Format: Article
Language:English
Subjects:
Adenocarcinoma
Biomarkers
Blood
Cancer
Cancer screening
Diagnostic systems
Gene expression
Medical screening
Neoplasms
Pancreas
Pancreatic cancer
Pancreatic carcinoma
Sensitivity
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: In patients with branch-duct intraductal papillary mucinous neoplasms (BD-IPMN), we aimed to develop a novel blood-based biomarker utilizing a gene-expression profile for the detection of pancreatic malignancies, such as IPMN-derived carcinoma (IPMC) or pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: We enrolled 40 patients with pancreatic tumors (24 BD-IPMNs, four IPMCs and 12 PDACs) and identified the characteristic gene-expression profiles in pancreatic malignancies. Subsequently, we constructed a gene-expression scoring system for the proper diagnosis of pancreatic malignancies. The result was validated in 14 patients (five IPMNs, three IPMCs and six PDACs). Results: The scoring system utilizing the expression levels of 13 genes showed high diagnostic yield (sensitivity=94.0%, specificity=92.0% and area under the curve=0.94), which was confirmed in the validation set. Furthermore, its diagnostic yield was not reduced even in early-stage pancreatic malignancies (sensitivity=85.0%, specificity=93.0% and area under the curve=0.88). Conclusion: We developed a blood-based gene expression scoring system for cancer screening in patients with BD-IPMNs.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14680